Martingale Asset Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Martingale Asset Management’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-4,763	Closed	-$657K	–	902
2021 Q4	$657K	Sell	4,763 -2,901	-38%	-$369K	0.01%	581
2021 Q3	$1.06M	Buy	7,664 +3,656	+91%	+$456K	0.01%	494
2021 Q2	$390K	Buy	+4,008	New	+$325K	﹤0.01%	666

Other funds holding BHVN

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Martingale Asset Management's BHVN Position: Q1 2022 in Review

Martingale Asset Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q1 2022, closing a stake of 4,763 shares — an estimated $657K sold.

Martingale Asset Management first reported a position in BHVN in Q2 2021 and held it in 3 quarters. The position peaked at $1.06M in Q3 2021. 307 funds tracked by Wall St. Rank hold BHVN as of Q1 2022.

Martingale Asset Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q1 2022 after selling out during the quarter.
Martingale Asset Management sold 4,763 Biohaven Pharmaceutical Holding Company Ltd. shares in Q1 2022, an estimated $657K.
Martingale Asset Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2021 and held it in 3 quarters.
Martingale Asset Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $1.06M in Q3 2021.
307 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q1 2022.

Based on Martingale Asset Management's 13F filing for Q1 2022, filed 12 May 2022.